BMS Pravachol REGRESS study shows slowing of coronary atherosclerosis progression.
BRISTOL PRAVACHOL TRIAL FINDS SLOWING OF CORONARY ATHEROSCEROSIS progression beginning within six months of therapy with the Bristol-Myers Squibb cholesterol-lowering drug pravastatin, as well as a reduction in clinical events at the end of two years. Results of the 885-patient Regression Growth Evaluation Statin Study (REGRESS), which enrolled men with mild to moderately elevated cholesterol levels, were presented March 21 at the annual meeting of the American College of Cardiology in New Orleans.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth